Insights
Fifteen+ years of
healthcare thinking.
Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
ESSENTIAL READING
Preclinical Licensing Deals Realized Value
- By Nicholas Buhay and Sarah Dolman
- Biopharma
Download a PDF of this paper here.
M&A deals in biopharma o…
Read more
An opinionated take on NEJM highlights for the first quarter of 2025
- By Marc Herant
- NEJM
Hematopoietic stem cell (HSC) gene therapy for hemophilia
Roctavian an…
Read more
Keys to harnessing the value of digital biomarkers in clinical trials
- By Lilian Zhang and Nikhil Bhojwani
- Biopharma ,
- Medtech ,
- Digital ,
Digital biomarkers are no longer just a pipe dream—they are here, and their use is potentially at an inflection point. However, successful implementation requires more than enthusiasm; it demands thoughtful strategies tailored to each clinical innovation, therapeutic area, and digital tool.
Read more
Kidney transplantation, improved but still a significant missed opportunity
- By Allison Cremer, Nikhil Bhojwani, and Jason Brauner
- Payers ,
- Providers ,
- Institutional
In order to make a more immediate and significant impact on dialysis and kidney waitlist, OPOs need to ensure that significantly more potential donors are identified, and all necessary steps are taken to ensure that a potential donor becomes an actual organ donor.
Read more
Commercial performance of AAV gene therapies: Market review and future implications
- By Dan Lee and Jason Brauner
- Biopharma
Introduction
In 2017, the FDA approved Luxturna for the treatment of L…
Read more
An opinionated take on NEJM highlights for the fourth quarter of 2024
- By Marc Herant
- NEJM
Preempting severe genetic disease
Around 2% of births come with a gene…
Read more
Incentivizing even small progress in Alzheimer’s therapy should be a priority
- By Martha Deja and Marc Herant
- Biopharma ,
- Institutional
Working paper:
Over the coming decades, Alzheimer’s disease threatens …
Read more
Artificial Intelligence for Pipeline Discovery and Beyond
- By Sarah Dolman
- Biopharma ,
- Digital ,
The biopharma industry is known for its high risk and potential high r…
Read more
An opinionated take on NEJM highlights for the third quarter of 2024
- By Marc Herant
- NEJM
The new Humira?
It’s not that often that you see industry-sponsored h…
Read more
SELECTED ENGAGEMENTS
Insight, put to work
Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.
- Institutional
Strategy for Statewide Health Information Exchange
A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable
HIE, Health IT,
- Medtech, Early Stage
Growth strategy for point-of-care testing
Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform
Growth, product market fit, value proposition
- Institutional
University Trials
Large university wanting to dramatically increase its clinical research footprint
Keep up with Recon Strategy Insights
Get an email each time we publish a new article